ABSTRACT
Because patients with bipolar disorder spend more time in the depressed phase than in the manic phase, many receive an incorrect diagnosis of unipolar major depression and receive inadequate or improper treatment for it, leading to a dramatically increased risk of morbidity and suicide. Greater diagnostic accuracy is needed.
Footnotes
↵* Dr. Muzina has disclosed that he has received honoraria for teaching, speaking, consulting, or serving on advisory committees or review panels for the AstraZeneca, Eli Lilly, GlaxoSmithKline, and Pfizer corporations.
↵† Dr. Manning has disclosed receiving honoraria for teaching, speaking, and consulting for the AstraZeneca and Eli Lilly corporations.
↵‡ Dr. Calabrese has disclosed that he has received honoraria, consulting fees, or research support from Abbott Pharmaceuticals, AstraZeneca, Bristol Myers Squibb/Otsuka, Ciba-Geigy, Eli Lilly, GlaxoSmithKline, Janssen, MacArthur Foundation, Merck, National Alliance for Research in Schizophrenia and Affective Disorders, National Institutes of Mental Health, Novartis, Parke Davis/Warner Lambert, Robert Wood Johnson Pharmaceutical Research Institute, Sandoz, Shire Laboratories, SmithKline Beecham, Stanley Foundation, TAP Holdings, Teva Pharmaceuticals, UCB Pharma, and Wyeth Ayerst Pharmaceuticals.
- Copyright © 2007 The Cleveland Clinic Foundation. All Rights Reserved.